Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Daiichi Sankyo Company Limited
Daiichi Sankyo Company Limited_20100107
Daiichi Sankyo Company Limited_20100121
Daiichi Sankyo Company Limited_20100114

Daiichi Sankyo Company Limited patents


Recent patent applications related to Daiichi Sankyo Company Limited. Daiichi Sankyo Company Limited is listed as an Agent/Assignee. Note: Daiichi Sankyo Company Limited may have other listings under different names/spellings. We're not affiliated with Daiichi Sankyo Company Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "D" | Daiichi Sankyo Company Limited-related inventors


Anti-trop2 antibody-drug conjugate

It is intended to provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. There is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-TROP2 antibody via a linker having a... Daiichi Sankyo Company Limited

Antibody-drug conjugate produced by binding through linker having hydrophilic structure

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula (I) is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- or -L1-L2-LP-... Daiichi Sankyo Company Limited

6-morpholinyl-2-pyrazolyl-9h-purine derivatives and their use as pi3k inhibitors

Particularly, the present invention provides a compound of formula (I) as inhibitors of phosphatidylinositol-3-kinase (PI3K), which can be used for treating or preventing inflammatory, autoimmune, orphan and hyperproliferative disease and disorder.... Daiichi Sankyo Company Limited

Method for predicting responsiveness to phosphatidylserine synthase 1 inhibitor

It is intended to develop a therapeutic strategy for specifically targeting cancer cells having the functional suppression of PSS2. The present inventors have found that PSS1 and PSS2 are in a synthetic lethal relationship, and treatment inhibiting PSS1 serves as a promising approach for the treatment of cancer having the... Daiichi Sankyo Company Limited

Cationic lipid

The present invention provides a compound represented by the formula (Ia) as a novel cationic lipid that forms a lipid particle and also provides a lipid particle comprising the compound. The present invention further provides a nucleic acid lipid particle containing the lipid particle, and a pharmaceutical composition containing the... Daiichi Sankyo Company Limited

Solid preparation including antioxidant

An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is compound represented by... Daiichi Sankyo Company Limited

Pharmaceutical for prophylaxis or treatment of hypertension

A pharmaceutical for the prophylaxis or treatment of hypertension or a disease derived from hypertension. The pharmaceutical is characterized by comprising (i) a specific mineralocorticoid receptor antagonist and (ii) one or more components selected from the following components (A) to (C), for administration simultaneously or separately at a time interval:... Daiichi Sankyo Company Limited

Antibody targeting osteoclast-related protein siglec-15

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of... Daiichi Sankyo Company Limited

Method for producing optically active valeric acid derivative

A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral... Daiichi Sankyo Company Limited

Terpenoid derivatives

It is intended to provide a novel terpenoid derivative that exhibits anti-inflammatory action and a cytoprotective action by activating the Keap1/Nrf2/ARE signaling pathway. The present invention provides terpenoid derivative A represented by the following formula (I):... Daiichi Sankyo Company Limited

Pharmaceutical composition for promotion of fibrinolysis

It is intended to provide a novel pharmaceutical composition that can promote fibrinolysis. The present invention provides a pharmaceutical composition for the promotion of fibrinolysis, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. The present invention further provides a pharmaceutical composition... Daiichi Sankyo Company Limited

Method for producing pyrrole derivative, and intermediate thereof

The present invention provides a method for producing an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, and an intermediate thereof. A method for producing an atropisomer of a pyrrole derivative using a compound represented by (B) [wherein R1 represents a C1-C4 alkyl group, and R2 represents... Daiichi Sankyo Company Limited

Ophthalmic aqueous composition

An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug... Daiichi Sankyo Company Limited

Synthesis of a compound that modulates kinases

or a salt thereof, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3. The disclosure also provides compounds and processes for the preparation of the compounds that are synthetic intermediates to the compound of formula I.... Daiichi Sankyo Company Limited

Solid composition of pyrrole carboxamide

An object is to provide a solid composition of stabilized pyrrole carboxamide. A means for achieving the object is a solid composition for medical use containing (S)-1-(2-hydroxyethyl)-4-methyl-N-[4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]-1H-pyrrole-3-carboxamide and an appropriate additive.... Daiichi Sankyo Company Limited

Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor

It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein.... Daiichi Sankyo Company Limited

Method of using a peptide library

The present invention provides a peptide selected from the following (i) and (ii): (i) a peptide having the amino acid sequence represented by SEQ ID NO: 1 in the Sequence Listing; and (ii) a peptide having an amino acid sequence derived from the amino acid sequence represented by SEQ ID... Daiichi Sankyo Company Limited

Pharmaceutical composition for suppression of thromboembolism after stent placement

It is intended to provide a novel pharmaceutical composition that can suppress thromboembolism after stent placement. The present invention provides a pharmaceutical composition for the suppression of thromboembolism after stent placement, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt.... Daiichi Sankyo Company Limited

Method for producing optically active valeric acid derivative

A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral... Daiichi Sankyo Company Limited

Salt of dicarboxylic acid compound

It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. The solution is crystals, or hydrate thereof, of a salt of a compound represented by formula (I).... Daiichi Sankyo Company Limited

Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors

Provided are gene signatures that are predictive of the sensitivity of a cancer or tumor to an MDM2i or an antagonist of the MDM2-p53 interaction. Differentially expressed genes in the provided gene signatures serve as biomarkers for determining and assessing the sensitivity of cancer and tumor samples to treatment or... Daiichi Sankyo Company Limited

Pharmaceutical composition having abuse deterrent properties

An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides... Daiichi Sankyo Company Limited

Sustained-release pharmaceutical composition for treatment and prevention of eye disease

The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid... Daiichi Sankyo Company Limited

Polynucleotides and polypeptide sequences involved in the process of bone remodeling

This invention relates, in part, to unique and newly identified genetic polynucleotides involved in the process of bone remodeling; variants and derivatives of the polynucleotides and corresponding polypeptides; uses of the polynucleotides, polypeptides, variants and derivatives; and methods and compositions for the amelioration of symptoms caused by bone remodeling disorders.... Daiichi Sankyo Company Limited

Pyridine compounds

The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I): wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3... Daiichi Sankyo Company Limited

Crystal of pyrrole derivative and producing the same

The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the... Daiichi Sankyo Company Limited

Anti-orai1 antibody

It is intended to provide a therapeutic and/or prophylactic agent for transplant rejections, immunological diseases, allergic diseases, inflammatory diseases, thrombosis, cancers, etc., targeting human Orai1. The present invention provides, for example, a pharmaceutical composition comprising an antibody that specifically recognizes human Orai1 and has the activity of inhibiting human T... Daiichi Sankyo Company Limited

Human anti-fgfr4 antibody

The present invention relates to novel antibodies against the FGF receptor 4 (FGFR4) and to the medical use thereof, in particular for the diagnosis prevention or treatment of diseases associated with FGFR expression, over expression or hyperactivity.... Daiichi Sankyo Company Limited

Method for treating cancer by combined use

It is intended to provide a medicament and a method for treating cancer comprising a compound having MDM2 inhibiting activity and a compound having FLT3 inhibiting activity in combination. The present invention provides a medicament comprising (3′R,4′S,5′R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a pharmaceutically acceptable salt thereof and N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt... Daiichi Sankyo Company Limited

Pyridine compounds

wherein R1 represents a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R2 and R3 are the same or different and each represent a hydrogen atom, an optionally substituted C1-6 alkyl group, or the like, R4 and R5 are the same or different and each represent a... Daiichi Sankyo Company Limited

Method for improved high-level secretory production of protein

The object of the present invention is to provide a production system that is capable of high-level secretory production of a protein (and in particular, a protein with a complicated structure such as a structure with S—S bonds) in a host cell such as yeast and is suitable for industrial... Daiichi Sankyo Company Limited

Pyridone derivative having tetrahydropyranylmethyl group

The present disclosure provides pyridone derivatives having a tetrahydropyranylmethyl group represented by the following formula (I) having various substituents, or salts thereof, or crystals of the compounds or the salts, wherein R1, R2, R3, R4, R5, W, X, Y, and Z are each as defined in the specification:... Daiichi Sankyo Company Limited

Tricyclic benzoxaboroles as antibacterial agents

The present invention provides a tricyclic compound represented by general formula (I), a pharmaceutical salt thereof, or a stereoisomer thereof exhibits excellent antibacterial activity against Gram-negative bacteria resistant bacteria thereof, and also being excellent in terms of safety. Furthermore, the present invention provides production processes, pharmaceutical compositions comprising a tricyclic... Daiichi Sankyo Company Limited

Method for producing spirooxindole derivative

... Daiichi Sankyo Company Limited

Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta

The present invention relates to the treatment of osteogenesis imperfecta with anti-Siglec-15 antibodies or antigen binding fragment thereof. Treatment of osteogenesis imperfecta type VI is particularly contemplated.... Daiichi Sankyo Company Limited

04/27/17 / #20170114035

Method for manufacturing neuraminic acid derivatives

[wherein R1 represents a C1-C19 alkyl group], or a pharmacologically acceptable salt thereof, using N-acetylneuraminic acid dihydrate as a starting raw material are provided.... Daiichi Sankyo Company Limited

04/20/17 / #20170107207

Aminopyrazolone derivative

The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.... Daiichi Sankyo Company Limited

03/23/17 / #20170080049

Medicine against growth failure induced by administration of steroid

Provided is a medicine for reducing and/or ameliorating growth failure induced by the administration of a steroid during a growth period, the medicine containing at least one type of natriuretic peptide receptor B (NPR-B) agonist as an active ingredient.... Daiichi Sankyo Company Limited

03/23/17 / #20170081334

Crystals of dispiropyrrolidine derivatives

Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3′R,4′S,5′R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.... Daiichi Sankyo Company Limited

03/23/17 / #20170081335

Crystals of dispiropyrrolidine derivatives

Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.... Daiichi Sankyo Company Limited

03/23/17 / #20170081336

Crystals of dispiropyrrolidine derivatives

Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3′R,4′S,5′R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.... Daiichi Sankyo Company Limited

03/23/17 / #20170081337

Crystals of dispiropyrrolidine derivatives

Crystals of a dispiropyrrolidine compound or a salt thereof which inhibits the action of Mdm2 are provided. The present invention provides crystals of (3′R,4'S,5′R)—N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide or a salt thereof which inhibits Mdm2 and has anti-tumor activity. The present invention also provides a medicament comprising the same.... Daiichi Sankyo Company Limited

03/16/17 / #20170073335

1,3-benzodioxole derivative

The present invention provides a compound having a particular chemical structure or a pharmacologically acceptable salt thereof which has an excellent inhibitory effect on EZH1 and/or EZH2 activity. The present invention provides a compound having a 1,3-benzodioxole structure represented by the general formula (I) or a pharmacologically acceptable salt thereof,... Daiichi Sankyo Company Limited

03/09/17 / #20170067899

Method for predicting responsiveness to cancer treatment using p300-inhibiting compound

It has been found that CBP and p300 are in the relationship of synthetic lethality, and treatment inhibiting p300 is a promising approach for the treatment of CBP-mutated cancer. It has also been revealed that this therapeutic strategy achieves efficient treatment based on companion diagnostics because a p300 inhibitor can... Daiichi Sankyo Company Limited

03/02/17 / #20170057915

Crystal of pyrrole derivative and producing the same

The present invention provides a production intermediate of an atropisomer of a pyrrole derivative having excellent mineralocorticoid receptor antagonistic activity, a method for producing the same, and a crystal thereof. A method for producing an atropisomer of a pyrrole derivative including a step of resolving a compound represented by the... Daiichi Sankyo Company Limited

02/23/17 / #20170050983

Method for producing inhibitor of activated blood coagulation factor x (fxa)

An object of the present invention is to provide a novel method for producing a compound, a salt thereof, or a hydrate of the compound or the salt, which is an FXa inhibitor. The object can be attained by a production method in which a production method via a compound... Daiichi Sankyo Company Limited

02/09/17 / #20170035906

(anti-her2 antibody)-drug conjugate

As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by... Daiichi Sankyo Company Limited

01/26/17 / #20170021031

Anti-her3 antibody-drug conjugate

To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula:... Daiichi Sankyo Company Limited

01/26/17 / #20170022220

High-purity crystals of active blood coagulation factor x (fxa) inhibitor

wherein, with regard to the content of impurities, the maximum content of any one type of impurity is 0.03% or less, and the total content of impurities is 0.13% or less, and wherein the high-purity crystals are obtained by a step of dissolving crystals in a solvent and then recrystallizing... Daiichi Sankyo Company Limited

01/19/17 / #20170015641

Dicarboxylic acid compound

It is an object of the present invention to provide a medicament for preventing or treating hyperphosphatemia. Solution: A compound represented by a general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, R1: a methyl group or the like, R2: a hydrogen atom or the like, R3:... Daiichi Sankyo Company Limited

01/05/17 / #20170001984

Cycloalkane derivatives

Disclosed herein are therapeutic agents and/or preventive agents for pain or therapeutic agents and/or preventive agents for a sodium channel associated disease. The present invention provides compounds represented by the following formula (I) or pharmacologically acceptable salts thereof:... Daiichi Sankyo Company Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Daiichi Sankyo Company Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Daiichi Sankyo Company Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###